Laboratory of Molecular Biology, Pathology Division, Multidisciplinary Institute for Investigation in Pediatric Pathologies (IMIPP), CONICET-GCBA, Ricardo Gutiérrez Children's Hospital, CABA, Buenos Aires, Argentina.
Liver Unit, Italian's Hospital of Buenos Aires; CABA, Buenos Aires, Argentina.
PLoS One. 2022 Jul 7;17(7):e0270911. doi: 10.1371/journal.pone.0270911. eCollection 2022.
Macrophage activation plays a key role in liver disease progression. Soluble CD163 (sCD163) is a specific macrophage activation biomarker useful for clinical estimating damage severity and predicting outcome in different liver conditions. sCD163 performance as a non-invasive marker of liver damage was evaluated in plasma samples at time of biopsy in 120 patients with different hepatic conditions (56 HCV, 20 HCV/HIV, 10 HBV and 34 MAFLD). sCD163 values were compared with those of healthy donors and analyzed related to histological damage. sCD163 together with other clinical parameters were used to create a logistical regression model to predict significant fibrosis. Only patients with viral hepatitis showed higher sCD163 values compared to the control group (HCV p<0.0001; HCV/HIV p<0.0001; HBV p = 0.0003), but no significant differences regarding fibrosis stages were observed. The proposed model predicts fibrosis severity using the logarithm sCD163 concentration, platelet count and age, it demonstrated to be a good marker for the HCV monoinfected group (AUROC 0.834) and an excellent one for the HCV/HIV co-infected group (AUROC 0.997). Moreover, the model displayed a diagnostic performance similar to FIB-4 in HCV cases and FIB-4 and APRI in HCV/HIV coinfected cases, and it even managed to correctly classify some cases that had been misclassified. The proposed model is able to determine, in a non-invasive way, the liver fibrosis stage of HCV and HCV/HIV patients, so after validation, it could be used in a complementary way in the clinical practice whenever APRI and FIB-4 failed to determine damage severity in HCV and HCV/HIV cases.
巨噬细胞活化在肝病进展中起着关键作用。可溶性 CD163（sCD163）是一种特定的巨噬细胞活化生物标志物，可用于临床评估损伤严重程度，并预测不同肝脏疾病的预后。在 120 名患有不同肝脏疾病（56 名 HCV、20 名 HCV/HIV、10 名 HBV 和 34 名 MAFLD）的患者的活检时血浆样本中评估了 sCD163 作为肝损伤的非侵入性标志物的性能。将 sCD163 值与健康供体的值进行比较，并分析与组织学损伤的关系。sCD163 与其他临床参数一起用于创建逻辑回归模型以预测显著纤维化。只有病毒性肝炎患者的 sCD163 值高于对照组（HCV p<0.0001；HCV/HIV p<0.0001；HBV p=0.0003），但纤维化分期无显著差异。该模型使用对数 sCD163 浓度、血小板计数和年龄预测纤维化严重程度，它被证明是 HCV 单一感染组的良好标志物（AUROC 0.834），也是 HCV/HIV 合并感染组的优秀标志物（AUROC 0.997）。此外，该模型在 HCV 病例中的表现与 FIB-4 相似，在 HCV/HIV 合并感染病例中的表现与 FIB-4 和 APRI 相似，甚至可以正确分类一些被误诊的病例。该模型能够以非侵入性的方式确定 HCV 和 HCV/HIV 患者的肝纤维化分期，因此在验证后，它可以在 APRI 和 FIB-4 无法确定 HCV 和 HCV/HIV 病例的损伤严重程度时，以补充方式在临床实践中使用。
